Aerie Pharmaceuticals Inc (AERI) 29.73 $AERI
Spin Doctors; Data And Market Projections From Aerie Pharmaceuticals, Inc. Are Too Optimistic
Sirius Capital - Seeking Alpha - Fri Dec 12, 7:00AM CST
During the Cold War era there was a famous joke about a race between a US and a USSR runner in which the American crossed the finish line first. The headline in the Communist party newspaper 'Pravda' had read 'In an international race, the Soviet...
AERI: 29.73 (-1.12)
Aerie Pharma completes enrollment in Rhopressa Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 7:47AM CST
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals Completes Enrollment in Phase 3 Registration Trial ("Rocket 1"
of Rhopressa(TM), Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma
Business Wire - Tue Dec 02, 5:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today the completion of enrollment in the Company's 400-patient Phase 3 registration trial ("Rocket 1" of Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Rocket 1 and a second Phase 3 registration trial ("Rocket 2" will measure efficacy over three months. The primary efficacy endpoint of the trials is to demonstrate non-inferiority of IOP lowering for Rhopressa(TM) compared to timolol. Timolol is the most widely used comparator in registration trials for glaucoma. In addition, the Company is conducting a safety-only study in Canada, named "Rocket 3."
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals to Present at the Piper Jaffray 26th Annual Healthcare Conference
Business Wire - Mon Nov 24, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Richard Rubino, chief financial officer, will present in a fireside chat discussion at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014 at 11:30 a.m. Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and business update.
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals to Present at the 2014 Stifel Nicolaus Annual Healthcare Conference
Business Wire - Wed Nov 12, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer will present at the 2014 Stifel Nicolaus Annual Healthcare Conference on Tuesday, November 18, 2014 at 8:35 a.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 8:40PM CST
AERI: 29.73 (-1.12)
Aerie posts 3Q loss
Automated Insights - Tue Nov 11, 3:27PM CST
RESEARCH TRIANGLE PARK, N.C. (AP) _ Aerie Pharmaceuticals Inc. (AERI) on Tuesday reported a loss of $13.1 million in its third quarter.
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals misses by $0.13
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:13PM CST
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Business and Product Development Update
Business Wire - Tue Nov 11, 3:05PM CST
--Rhopressa(TM) and Roclatan(TM) Development Programs Advancing
AERI: 29.73 (-1.12)
Aerie Pharma reports November 11
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:07AM CDT
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 11, 2014
Business Wire - Tue Oct 28, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced today that its third quarter 2014 financial results will be released after the market closes on Tuesday, November 11, 2014. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals names Dr Benjamin F. McGraw to board
M2 - Tue Oct 07, 7:01AM CDT
Pharmaceutical company Aerie Pharmaceuticals (NasdaqGM:AERI) revealed on Monday the addition of Benjamin F. McGraw, III, PharmD to its board of directors and as a member of its Audit Committee, effective 30 September 2014.
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals Elects Benjamin F. McGraw, III to Its Board of Directors
Business Wire - Mon Oct 06, 3:45PM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that Benjamin F. McGraw, III, Pharm.D., has been elected to the Company's Board of Directors and as a member of the Audit Committee, effective September 30, 2014. Dr. McGraw brings more than 30 years of experience in the life sciences, responsible for advancing breakthrough technologies and numerous development-stage programs through commercialization.
AERI: 29.73 (-1.12)
Aerie Announces Closing of $125 Million Convertible Notes Financing
Business Wire - Tue Sep 30, 3:05PM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it has closed its $125 million financing with Deerfield Management Company L.P. ("Deerfield" , a current Aerie shareholder. Under the terms of the financing, the notes are secured and will accrue interest at a rate of 1.75% per annum until maturity in September of 2021. The notes are convertible at a conversion price representing a 30% premium over the closing price of Aerie stock on September 8, 2014, resulting in a conversion price of $24.80 per share.
AERI: 29.73 (-1.12)
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - 22 Drug Profiles from 11 Companies
M2 - Fri Sep 12, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c97xhn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Santen Pharmaceutical Co., Ltd. - Oxford BioMedica plc - Sylentis S.A. - Ono Pharmaceutical Co., Ltd. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Amakem NV Drug Profiles - tafluprost - (tafluprost timolol maleate) - latanoprostene bunod - latanoprost - OPC-1085EL - trabodenoson - SYL-040012 - RO-5093151 - latanoprost - AR-13324 - AMA-0076 - ONO-9054 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - latanoprost SR - Glaucoma-GT - ATS-8535 - Small Molecule for Glaucoma For more information visit http://www.researchandmarkets.com/research/c97xhn/openangle
AERI: 29.73 (-1.12)
Aerie expects USD125m from convertible notes financing
M2 - Tue Sep 09, 6:42AM CDT
Pharmaceutical company Aerie Pharmaceuticals (NasdaqGM:AERI) revealed on Tuesday the receipt of a USD125m financing commitment from its current shareholder, Deerfield Management Company.
AERI: 29.73 (-1.12)
Deerfield Management Company Announces a $125 Million Facility with Aerie Pharmaceuticals
Business Wire - Tue Sep 09, 5:03AM CDT
Deerfield Management Company announced today it has committed to invest $125 million in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) through senior secured convertible notes. The financing is expected to be funded before the end of September 2014, subject to customary closing conditions. The facility provides Aerie with capital for the continued advancement of development activities for the Company's clinical-stage product pipeline, general corporate purposes and strategic growth opportunities.
AERI: 29.73 (-1.12)
Aerie Announces $125 Million Convertible Notes
Business Wire - Tue Sep 09, 5:00AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it has received a $125 million financing commitment from Deerfield Management Company L.P. ("Deerfield" , a current Aerie shareholder. The financing is expected to be funded before the end of September 2014, subject to customary closing conditions. Aerie intends to use the proceeds from this financing for the continued advancement of development activities for the Company's clinical-stage product pipeline, general corporate purposes and strategic growth opportunities.
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals to Host Investor Day on September 10, 2014
Business Wire - Thu Sep 04, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that the Company will host a live webcast in conjunction with its Investor Day on Wednesday, September 10, 2014 at 12:00p.m. ET in New York, NY.
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals Inc. Initiates Phase 3 Safety-Only Registration Trial in Canada of Rhopressa(TM) in Patients with Glaucoma
Business Wire - Wed Sep 03, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on August 29, dosing commenced of the first patients enrolled in the Company's Phase 3 registration trial in Canada of Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The study, named "Rocket 3," is designed to evaluate safety and tolerability of Rhopressa(TM) in patients over a 12 month period and is part of a broad Phase 3 program being conducted by Aerie. The Company recently announced the commencement of two Phase 3 trials in the United States, "Rocket 1" and "Rocket 2," which are focused on demonstrating non-inferiority of IOP lowering for Rhopressa(TM) compared to timolol, the most widely used comparator in registration trials for glaucoma. Aerie anticipates total enrollment of approximately 1,300 patients in the three Phase 3 trials of Rhopressa(TM).
AERI: 29.73 (-1.12)
Spin Doctors; Data And Market Projections From Aerie Pharmaceuticals, Inc. Are Too Optimistic
Sirius Capital - Seeking Alpha - Fri Dec 12, 7:00AM CST
During the Cold War era there was a famous joke about a race between a US and a USSR runner in which the American crossed the finish line first. The headline in the Communist party newspaper 'Pravda' had read 'In an international race, the Soviet...
AERI: 29.73 (-1.12)
Aerie Pharma completes enrollment in Rhopressa Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 7:47AM CST
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals Completes Enrollment in Phase 3 Registration Trial ("Rocket 1"
of Rhopressa(TM), Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma Business Wire - Tue Dec 02, 5:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today the completion of enrollment in the Company's 400-patient Phase 3 registration trial ("Rocket 1"
of Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Rocket 1 and a second Phase 3 registration trial ("Rocket 2" will measure efficacy over three months. The primary efficacy endpoint of the trials is to demonstrate non-inferiority of IOP lowering for Rhopressa(TM) compared to timolol. Timolol is the most widely used comparator in registration trials for glaucoma. In addition, the Company is conducting a safety-only study in Canada, named "Rocket 3." AERI: 29.73 (-1.12)
Aerie Pharmaceuticals to Present at the Piper Jaffray 26th Annual Healthcare Conference
Business Wire - Mon Nov 24, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Richard Rubino, chief financial officer, will present in a fireside chat discussion at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014 at 11:30 a.m. Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and business update.
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals to Present at the 2014 Stifel Nicolaus Annual Healthcare Conference
Business Wire - Wed Nov 12, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer will present at the 2014 Stifel Nicolaus Annual Healthcare Conference on Tuesday, November 18, 2014 at 8:35 a.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 8:40PM CST
AERI: 29.73 (-1.12)
Aerie posts 3Q loss
Automated Insights - Tue Nov 11, 3:27PM CST
RESEARCH TRIANGLE PARK, N.C. (AP) _ Aerie Pharmaceuticals Inc. (AERI) on Tuesday reported a loss of $13.1 million in its third quarter.
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals misses by $0.13
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:13PM CST
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Business and Product Development Update
Business Wire - Tue Nov 11, 3:05PM CST
--Rhopressa(TM) and Roclatan(TM) Development Programs Advancing
AERI: 29.73 (-1.12)
Aerie Pharma reports November 11
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:07AM CDT
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 11, 2014
Business Wire - Tue Oct 28, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced today that its third quarter 2014 financial results will be released after the market closes on Tuesday, November 11, 2014. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals names Dr Benjamin F. McGraw to board
M2 - Tue Oct 07, 7:01AM CDT
Pharmaceutical company Aerie Pharmaceuticals (NasdaqGM:AERI) revealed on Monday the addition of Benjamin F. McGraw, III, PharmD to its board of directors and as a member of its Audit Committee, effective 30 September 2014.
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals Elects Benjamin F. McGraw, III to Its Board of Directors
Business Wire - Mon Oct 06, 3:45PM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that Benjamin F. McGraw, III, Pharm.D., has been elected to the Company's Board of Directors and as a member of the Audit Committee, effective September 30, 2014. Dr. McGraw brings more than 30 years of experience in the life sciences, responsible for advancing breakthrough technologies and numerous development-stage programs through commercialization.
AERI: 29.73 (-1.12)
Aerie Announces Closing of $125 Million Convertible Notes Financing
Business Wire - Tue Sep 30, 3:05PM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it has closed its $125 million financing with Deerfield Management Company L.P. ("Deerfield"
, a current Aerie shareholder. Under the terms of the financing, the notes are secured and will accrue interest at a rate of 1.75% per annum until maturity in September of 2021. The notes are convertible at a conversion price representing a 30% premium over the closing price of Aerie stock on September 8, 2014, resulting in a conversion price of $24.80 per share. AERI: 29.73 (-1.12)
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - 22 Drug Profiles from 11 Companies
M2 - Fri Sep 12, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c97xhn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Santen Pharmaceutical Co., Ltd. - Oxford BioMedica plc - Sylentis S.A. - Ono Pharmaceutical Co., Ltd. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Amakem NV Drug Profiles - tafluprost - (tafluprost timolol maleate) - latanoprostene bunod - latanoprost - OPC-1085EL - trabodenoson - SYL-040012 - RO-5093151 - latanoprost - AR-13324 - AMA-0076 - ONO-9054 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - latanoprost SR - Glaucoma-GT - ATS-8535 - Small Molecule for Glaucoma For more information visit http://www.researchandmarkets.com/research/c97xhn/openangle
AERI: 29.73 (-1.12)
Aerie expects USD125m from convertible notes financing
M2 - Tue Sep 09, 6:42AM CDT
Pharmaceutical company Aerie Pharmaceuticals (NasdaqGM:AERI) revealed on Tuesday the receipt of a USD125m financing commitment from its current shareholder, Deerfield Management Company.
AERI: 29.73 (-1.12)
Deerfield Management Company Announces a $125 Million Facility with Aerie Pharmaceuticals
Business Wire - Tue Sep 09, 5:03AM CDT
Deerfield Management Company announced today it has committed to invest $125 million in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) through senior secured convertible notes. The financing is expected to be funded before the end of September 2014, subject to customary closing conditions. The facility provides Aerie with capital for the continued advancement of development activities for the Company's clinical-stage product pipeline, general corporate purposes and strategic growth opportunities.
AERI: 29.73 (-1.12)
Aerie Announces $125 Million Convertible Notes
Business Wire - Tue Sep 09, 5:00AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it has received a $125 million financing commitment from Deerfield Management Company L.P. ("Deerfield"
, a current Aerie shareholder. The financing is expected to be funded before the end of September 2014, subject to customary closing conditions. Aerie intends to use the proceeds from this financing for the continued advancement of development activities for the Company's clinical-stage product pipeline, general corporate purposes and strategic growth opportunities. AERI: 29.73 (-1.12)
Aerie Pharmaceuticals to Host Investor Day on September 10, 2014
Business Wire - Thu Sep 04, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that the Company will host a live webcast in conjunction with its Investor Day on Wednesday, September 10, 2014 at 12:00p.m. ET in New York, NY.
AERI: 29.73 (-1.12)
Aerie Pharmaceuticals Inc. Initiates Phase 3 Safety-Only Registration Trial in Canada of Rhopressa(TM) in Patients with Glaucoma
Business Wire - Wed Sep 03, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on August 29, dosing commenced of the first patients enrolled in the Company's Phase 3 registration trial in Canada of Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The study, named "Rocket 3," is designed to evaluate safety and tolerability of Rhopressa(TM) in patients over a 12 month period and is part of a broad Phase 3 program being conducted by Aerie. The Company recently announced the commencement of two Phase 3 trials in the United States, "Rocket 1" and "Rocket 2," which are focused on demonstrating non-inferiority of IOP lowering for Rhopressa(TM) compared to timolol, the most widely used comparator in registration trials for glaucoma. Aerie anticipates total enrollment of approximately 1,300 patients in the three Phase 3 trials of Rhopressa(TM).
AERI: 29.73 (-1.12)
